Olaparib for advanced breast cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Torre LA , Siegel RL , Ward EM , Jemal A . Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol. Biomarkers Prev. 25(1), 16–27 (2016).
  MedlineGoogle Scholar
• 2. Gobbini E , Ezzalfani M , Dieras V et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur. J. Cancer 96, 17–24 (2018).
  MedlineGoogle Scholar
• 3. Schmid P , Adams S , Rugo HS et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379(22), 2108–2121 (2018).
  Medline CASGoogle Scholar
• 4. Wooster R , Weber BL . Breast and ovarian cancer. N. Engl. J. Med. 348(23), 2339–2347 (2003).
  Medline CASGoogle Scholar
• 5. Wooster R , Bignell G , Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2 . Nature 378(6559), 789–792 (1995).
  Medline CASGoogle Scholar
• 6. Miki Y , Swensen J , Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182), 66–71 (1994).
  Medline CASGoogle Scholar
• 7. Spurdle AB , Couch FJ , Parsons MT et al. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA and ENIGMA consortia. Breast Cancer Res. 16(6), 3419–014-0474-y (2014).
  Google Scholar
• 8. Farmer H , McCabe N , Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917–921 (2005).
  Medline CASGoogle Scholar
• 9. Lord CJ , Ashworth A . The DNA damage response and cancer therapy. Nature 481(7381), 287–294 (2012).
  Medline CASGoogle Scholar
• 10. Lord CJ , Ashworth A . BRCAness revisited. Nat. Rev. 16(2), 110–120 (2016).
  CASGoogle Scholar
• 11. Lord CJ , Ashworth A . PARP inhibitors: synthetic lethality in the clinic. Science 355(6330), 1152–1158 (2017).
  Medline CASGoogle Scholar
• 12. McCabe N , Turner NC , Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66(16), 8109–8115 (2006).
  Medline CASGoogle Scholar
• 13. Bryant HE , Schultz N , Thomas HD et al. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035), 913–917 (2005).
  Medline CASGoogle Scholar
• 14. Aredia F , Scovassi AI . Poly(ADP-ribose): a signaling molecule in different paradigms of cell death. Biochem. Pharmacol. 92(1), 157–163 (2014).
  Medline CASGoogle Scholar
• 15. Schreiber V , Dantzer F , Ame J-C , de Murcia G . Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7(7), 517–528 (2006).
  Medline CASGoogle Scholar
• 16. De Vos M , Schreiber V , Dantzer F . The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem. Pharmacol. 84(2), 137–146 (2012).
  MedlineGoogle Scholar
• 17. Murai J , Huang SY , Das BB et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72(21), 5588–5599 (2012).
  Medline CASGoogle Scholar
• 18. Griguolo G , Dieci MV , Guarneri V , Conte P . Olaparib for the treatment of breast cancer. Expert Rev. Anticancer Ther. 18(6), 519–530 (2018).
  Medline CASGoogle Scholar
• 19. Miglietta F , Dieci MV , Griguolo G , Guarneri V , Conte PF . Chemotherapy for advanced HER2-negative breast cancer: can one algorithm fit all? Cancer Treat. Rev. 60, 100–108 (2017).
  Medline CASGoogle Scholar
• 20. Robson M , Im SA , Senkus E et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377(6), 523–533 (2017). •• OlympiAD Phase III trial reporting progression-free survival benefit for germline BRCA-mutated HER2-negative advanced breast cancer patients treated with olaparib as compared to standard chemotherapy.
  Medline CASGoogle Scholar
• 21. Robson ME , Tung N , Conte P et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. 30(4), 558–566 (2019). •• Overall survival data from the OlympiAD Phase III trial randomizing germline BRCA-mutated HER2-negative advanced breast cancer patients to olaparib versus standard chemotherapy.
  Medline CASGoogle Scholar
• 22. Sammons S , Tan TJY , Traina TA et al. Dora: A randomized Phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC). J. Clin. Oncol. 37(Suppl. 15), TPS1113–TPS1113 (2019).
  Google Scholar
• 23. Tutt A , Tovey H , Cheang MCU et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat. Med. 24(5), 628–637 (2018).
  Medline CASGoogle Scholar
• 24. Diéras VC , Han HS , Kaufman B et al. LBA9 - Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. Ann. Oncol. 30(Suppl.5), v857–v858 (2019).
  Google Scholar
• 25. Domchek S , Postel-Vinay S , Im S-A et al. 1191O Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Ann. Oncol. 30(Suppl.5), v477 (2019). • Phase I/II trial testing the use of olaparib in combination with durvalumab for the treatment of advanced breast cancer in germline BRCA-mutated patients.
  Google Scholar
• 26. Domchek S , Postel-Vinay S , Im S-A et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX . AACR, PA, USA Cancer Res. 79 (4 Suppl), Abstract nr PD5-04 (2019).
  Google Scholar
• 27. Telli ML , Timms KM , Reid J et al. Homologous recombination deficiency (hrd) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 22(15), 3764–3773 (2016).
  Medline CASGoogle Scholar
• 28. Davies H , Glodzik D , Morganella S et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23(4), 517–525 (2017).
  Medline CASGoogle Scholar
• 29. Earl HM , Vallier AL , Qian W et al. PARTNER: randomised, Phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients. J. Clin. Oncol. 35(15), TPS591 (2017).
  Google Scholar
• 30. Castroviejo‐Bermejo M , Cruz C , Llop‐Guevara A et al. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol. Med. 10(12), e9172 (2018).
  MedlineGoogle Scholar
• 31. Cruz C , Castroviejo-Bermejo M , Gutiérrez-Enríquez S et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann. Oncol. 29(5), 1203–1210 (2018).
  Medline CASGoogle Scholar
• 32. Menear KA , Adcock C , Boulter R et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem. 51(20), 6581–6591 (2008).
  Medline CASGoogle Scholar
• 33. Evers B , Drost R , Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14(12), 3916–3925 (2008).
  Medline CASGoogle Scholar
• 34. Rottenberg S , Jaspers JE , Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105(44), 17079–17084 (2008).
  Medline CASGoogle Scholar
• 35. Fong PC , Boss DS , Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123–134 (2009). •• Pivotal Phase I trial of olaparib for mixed advanced solid tumors.
  Medline CASGoogle Scholar
• 36. Mateo J , Moreno V , Gupta A et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Target. Oncol. 11(3), 401–415 (2016).
  Medline CASGoogle Scholar
• 37. Plummer R , Swaisland H , Leunen K et al. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 76(4), 723–729 (2015).
  Medline CASGoogle Scholar
• 38. Rolfo C , Swaisland H , Leunen K et al. Effect of food on the pharmacokinetics of olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors. Adv. Ther. 32(6), 510–522 (2015).
  Medline CASGoogle Scholar
• 39. Rolfo C , de Vos-Geelen J , Isambert N et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumors and renal impairment. Clin. Pharmacokinet. 58(9), 1165–1174 (2019).
  Medline CASGoogle Scholar
• 40. Rolfo C , de Vos-Geelen J , Isambert N et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumors and hepatic or renal impairment. Clin. Pharmacol. Ther. 101(S1), S85–S86 (2017).
  Google Scholar
• 41. Lee JM , Hays JL , Annunziata CM et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J. Natl Cancer Inst. 106(6), dju089 (2014).
  MedlineGoogle Scholar
• 42. Balmana J , Tung NM , Isakoff SJ et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 25(8), 1656–1663 (2014).
  Medline CASGoogle Scholar
• 43. Van der Noll R , Marchetti S , Steeghs N et al. Long-term safety and anti-tumor activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. Br. J. Cancer 113(3), 396–402 (2015).
  Medline CASGoogle Scholar
• 44. Lee JM , Hays JL , Chiou VL et al. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget 8(45), 79175–79187 (2017).
  MedlineGoogle Scholar
• 45. Lee JM , Peer CJ , Yu M et al. Sequence-specific pharmacokinetic and pharmacodynamic Phase I/Ib study of olaparib tablets and carboplatin in women’s cancer. Clin. Cancer Res. 23(6), 1397–1406 (2017).
  Medline CASGoogle Scholar
• 46. Dent RA , Lindeman GJ , Clemons M et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 15(5), R88 (2013).
  MedlineGoogle Scholar
• 47. Del Conte G , Sessa C , von Moos R et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumors. Br. J. Cancer 111(4), 651–659 (2014).
  MedlineGoogle Scholar
• 48. Liu JF , Tolaney SM , Birrer M et al. A Phase I trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur. J. Cancer 49(14), 2972–2978 (2013).
  Medline CASGoogle Scholar
• 49. Westin SN , Litton JK , Williams RA et al. Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. J. Clin. Oncol. 36(Suppl. 15), 5504–5504 (2018).
  Google Scholar
• 50. Tutt A , Robson M , Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737), 235–244 (2010). • Phase II trial testing the use of olaparib for the treatment of advanced breast cancer in germline BRCA-mutated patients.
  Medline CASGoogle Scholar
• 51. Gelmon KA , Tischkowitz M , Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a Phase II, multicentre, open-label, non-randomised study. Lancet.Oncol. 12(9), 852–861 (2011).
  Medline CASGoogle Scholar
• 52. Kaufman B , Shapira-Frommer R , Schmutzler RK et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J. Clin. Oncol. 33(3), 244–250 (2015).
  Medline CASGoogle Scholar
• 53. Cruz C , Llop-Guevara A , Garber JE et al. Multicenter Phase II study of lurbinectedin in BRCA -mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy. J. Clin. Oncol. 36(31), 3134–3143 (2018).
  Medline CASGoogle Scholar
• 54. Geenen JJJ , Dackus G , Schouten PC et al. A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. J. Clin. Oncol. 37(Suppl. 15), 3118 (2019).
  Google Scholar
• 55. Schouten PC , Dackus GMHE , Marchetti S et al. A Phase I followed by a randomized Phase II trial of two cycles carboplatin–olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. Trials. 17(1), 293 (2016).
  MedlineGoogle Scholar
• 56. Fasching PA , Jackisch C , Rhiem K et al. GeparOLA: A randomized Phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). J. Clin. Oncol. 37(Suppl. 15), 506–506 (2019).
  Google Scholar
• 57. Yonemori K , Shimomura A , Yasojima H et al. A Phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. Eur. J. Cancer 109, 84–91 (2019).
  Medline CASGoogle Scholar
• 58. Bitler BG , Watson ZL , Wheeler LJ , Behbakht K . PARP inhibitors: clinical utility and possibilities of overcoming resistance. Gynecol. Oncol. 147(3), 695–704 (2017).
  Medline CASGoogle Scholar
• 59. Konstantinopoulos PA , Barry WT , Birrer M et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 20(4), 570–580 (2019).
  Medline CASGoogle Scholar
• 60. Michalarea V , Roda D , Drew Y et al. Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans, LA. AACR, PA, USA Cancer Res, 76 (Suppl. 14), CT010–CT010 (2016).
  Google Scholar
• 61. Matulonis UA , Wulf GM , Barry WT et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer. Ann. Oncol. 28(3), mdw672 (2016).
  Google Scholar
• 62. Neckers L . Heat shock protein 90: the cancer chaperone. J. Biosci. 32(3), 517–530 (2007).
  Medline CASGoogle Scholar
• 63. Higuchi T , Flies DB , Marjon NA et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol. Res. 3(11), 1257–1268 (2015).
  Medline CASGoogle Scholar
• 64. Domchek S , Postel-Vinay S , Im S-A et al. MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancercohorts [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4–8; San Antonio, TX. AACR, PA, USA Cancer Res. 79(4 Suppl), OT3-05-03 (2019).
  Google Scholar
• 65. Jagsi R , Griffith KA , Bellon JR et al. Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: the TBCRC 024 Phase I multicenter study. J. Clin. Oncol. 36(13), 1317–1322 (2018).
  Medline CASGoogle Scholar
• 66. Lee JM , Cimino-Mathews A , Peer CJ et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1–3 inhibitor cediranib in women’s cancers: a dose-escalation, phase i study. J. Clin. Oncol. 35(19), 2193–2202 (2017).
  Medline CASGoogle Scholar
• 67. Mitri ZI , Vuky J , Kemmer KA et al. A Phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer. J. Clin. Oncol. 37(Suppl. 15), TPS1111–TPS1111 (2019).
  Google Scholar
• 68. Robson M , Ruddy KJ , SA IM et al. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur. J. Cancer 120, 20–30 (2019). • Patient-reported outcome from the OlympiAD Phase III trial randomizing germline BRCA-mutated HER2-negative advanced breast cancer patients to olaparib versus standard chemotherapy.
  Medline CASGoogle Scholar
• 69. Gelmon KA , Walker GP , Fisher GV , McCutcheon SC . 367TiPLUCY: A Phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation. Ann. Oncol. 29(Suppl.8), viii120 (2018).
  Google Scholar
• 70. Litton JK , Rugo HS , Ettl J et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379(8), 753–763 (2018).
  Medline CASGoogle Scholar
• 71. Ettl J , Quek RGW , Lee KH et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA Phase III trial. Ann. Oncol. 29(9), 1939–1947 (2018).
  Medline CASGoogle Scholar
• 72. Zhou D , Li J , Learoyd M et al. Efficacy and safety exposure‐response analyses of olaparib capsule and tablet formulations in oncology patients. Clin. Pharmacol. Ther. 105(6), 1492–1500 (2019).
  Medline CASGoogle Scholar
• 73. Lee CK , Scott C , Lindeman GJ et al. Phase I trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer and non-BRCA ovarian cancer. Br. J. Cancer 120(3), 279–285 (2019).
  Medline CASGoogle Scholar
• 74. Ledermann JA , Harter P , Gourley C et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, Phase II trial. Lancet.Oncol. 17(11), 1579–1589 (2016).
  Medline CASGoogle Scholar
• 75. Ledermann J , Harter P , Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised Phase II trial. Lancet.Oncol. 15(8), 852–861 (2014).
  Medline CASGoogle Scholar
• 76. Moore K , Colombo N , Scambia G et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379(26), 2495–2505 (2018).
  Medline CASGoogle Scholar